Lead Product(s) : Vonafexor
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Vesalius Biocapital
Deal Size : $36.8 million
Deal Type : Series C Financing
ENYO Completes Series C to Advance Phase 2 Study in Alport Syndrome
Details : The proceeds will fund the ongoing ALPESTRIA-1 study evaluating EYP001 (vonafexor), a highly selective and oral FXR agonist, in patients with Alport syndrome.
Product Name : EYP001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 12, 2025
Lead Product(s) : Vonafexor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Vesalius Biocapital
Deal Size : $36.8 million
Deal Type : Series C Financing
Lead Product(s) : Odiparcil
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results show that odiparcil was associated with decreased glycosaminoglycan (GAG) accumulation as well as increased GAG excretion, and highlight its distribution in MPS VI disease-relevant tissues and organs.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 18, 2020
Lead Product(s) : Odiparcil
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Odiparcil
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Inventiva to Present Results from its Phase IIa Odiparcil Study
Details : The Phase IIa clinical study results in MPS VI adult patients showed the capacity of odiparcil to improve key clinical parameters such as corneal clouding and cardiac and respiratory functions.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 02, 2020
Lead Product(s) : Odiparcil
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable